07:00 , Aug 20, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes Paired box 4 (PAX4) Studies in mice suggest that enhancing levels of PAX4 could help treat diabetes. In murine pancreatic islets, Pax4 induced...
01:42 , Jan 16, 2009 |  BC Extra  |  Financial News

7TM raises $13.4 million

7TM (Horsholm, Denmark) raised DKK75 million ($13.4 million) in a private round through existing investors. 7TM has two compounds in Phase I/II testing to treat obesity: obinepitide , a synthetic analog of human hormones PYY3-36...
08:00 , Mar 6, 2008 |  BC Innovations  |  Distillery Techniques

This Week in Techniques

This week in techniques Approach Summary Licensing status Publication and contact information Cationic amino acid motifs for improving cell penetration of protein therapeutics Engineering as few as five arginine residues into a protein a-helix could...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Clinical News

Obinepitide: Phase I/II data

In a double-blind, placebo-controlled, dosing-ranging Phase I/II trial in obese patients, obinepitide reduced food intake. 7TM Pharma A/S , Horsholm, Denmark   Product: Obinepitide ( TM30338 )   Business: Endocrine   Molecular target: Neuropeptide Y...
07:00 , Jun 25, 2007 |  BioCentury  |  Product Development

De-risking obesity strategies

Although an FDA advisory committee's negative vote on sanofi-aventis Group 's Zimulti rimonabant signals a general increase in scrutiny of side effects resulting from centrally acting compounds in non-psychotropic indications, other companies in the space...
07:00 , Jun 18, 2007 |  BC Week In Review  |  Clinical News

Obinepitide: Phase II started

7TM began a double-blind, Swedish Phase II trial in 180 obese patients with BMI of 30-40 to compare subcutaneous obinepitide vs. placebo for 28 days. 7TM Pharma A/S , Copenhagen, Denmark   Product: Obinepitide (...
07:00 , Mar 26, 2007 |  BioCentury  |  Product Development

Targeting obesity

Targeting obesity Phase II anti-obesity agents are attacking the disease via multiple paths. A number of compounds are suppressing appetite by affecting neurotransmitters dopamine, noradrenaline, serotonin and histamine, including Obecure's betahistine, NeuroSearch's tesofensine and Orexigen's...
07:00 , Mar 26, 2007 |  BioCentury  |  Product Development

Early data

Early data Obesity Company Product 7TM TM30338 synthetic analog of human hormones PYY3-36 and pancreatic polypeptide Diet-induced obese (DIO) animals: TM30338 showed superior long-term reduction in body weight vs. PYY3-36 alone Alizyme/ Takeda Cetilistat lipase...
07:00 , Mar 26, 2007 |  BioCentury  |  Product Development

Metabolic Milestones

The increasing prevalence of metabolic diseases has become a growing concern as studies continue to draw links between them and a wide array of comorbidities. As new targets and pathways come to light, the race...
07:00 , Mar 26, 2007 |  BioCentury  |  Product Development

Reaching proof of concept

Reaching proof of concept Obesity Company Product Description Target/ Mechanism Milestones Alizyme Cetilistat (ATL-962) Lipase inhibitor Lipase Start Ph III 1H07 (A) Amylin Pramlintide/leptin Synthetic amylin analog/recombinant leptin Amylin receptor/leptin receptor Ph II data 07...